VISUAL IMPROVEMENT FOLLOWING INTRAVITREAL BEVACIZUMAB (AVASTIN) IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION

2006116 citationsJournal Article

Authors

Vincent Deramo · Ophthalmic Consultants of Long Island

James C. K. Lai · Ophthalmic Consultants of Long Island

David M. Fastenberg · Ophthalmic Consultants of Long Island

Abstract

Intravitreal bevacizumab has the potential for improvement in vision in both naive and previously treated eyes for at least 6 months. The benefit is more pronounced in eyes without prior pegaptanib and/or PDT.

Topics & Keywords

Retinal Diseases and Treatments Retinal Imaging and Analysis Retinal and Optic Conditions

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Retina

Volume 26, Issue 9, pp. 994-998

DOI: 10.1097/01.iae.0000244380.34082.67

Field-Weighted Citation Impact: 17.18

Command Palette